NYSE - Delayed Quote USD

Biohaven Ltd. (BHVN)

38.54

-0.18

(-0.46%)

At close: April 25 at 4:00 PM EDT

38.87

+0.33

(+0.86%)

After hours: April 25 at 6:40 PM EDT

Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN)

On April 24, 2024, Gregory Bailey, Director of Biohaven Ltd (NYSE:BHVN), purchased 25,503 shares of the company, as reported in a recent SEC Filing.

GuruFocus.com 9 hours ago

BHVN
-0.46%
Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)

Director Gregory Bailey has recently increased his stake in Biohaven Ltd (NYSE:BHVN) by purchasing 48,780 shares of the company's stock, according to a SEC Filing dated 2024-04-22.

GuruFocus.com 2 days ago

BHVN
-0.46%
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the closing of its underwritten public offering of 6,451,220 of its common shares, which includes the full exercise of the underwriters' option to purchase 841,463 additional common shares, at a public offering price of $41.00 per share. The gross proceeds from t

PR Newswire 3 days ago

BHVN
-0.46%
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public

PR Newswire 7 days ago

BHVN
-0.46%
Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology, today announced that it has commenced an underwritten public offering of $200 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an

PR Newswire 8 days ago

BHVN
-0.46%
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

Biohaven Ltd. (NYSE: BHVN) announced today that 20 abstracts, including 8 oral presentations and 12 posters, will be featured this weekend starting April 13th at the 2024 American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, Colorado. The presentations highlight Biohaven's leadership in neuroscience and extensive development programs evaluating novel therapies to treat neurological diseases, with abstracts covering programs that include Kv7 ion channel modulation, molecular

PR Newswire 12 days ago

BHVN
-0.46%
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?

The biotechnology scene is becoming difficult to ignore if you consider yourself a growth investor who seeks upside potential beyond just the numerous crowded artificial intelligence (AI) plays. Though there are still lower-cost AI stocks in the mega-cap universe, I’d argue that few are capable of the type of upside as some of the market’s most innovative biotechnology firms — like LLY, REGN, and BHVN. Further, the biotechnology scene stands out as one of the industries that can also be made mor

TipRanks 21 days ago

REGN

LLY

BHVN
-0.46%
Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock

In the last year, multiple insiders have substantially increased their holdings of Biohaven Ltd. ( NYSE:BHVN ) stock...

Simply Wall St. last month

BHVN
-0.46%
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.

PR Newswire last month

BHVN
-0.46%
A Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Key Insights The projected fair value for Biohaven is US$45.86 based on 2 Stage Free Cash Flow to Equity With US$49.50...

Simply Wall St. 2 months ago

BHVN
-0.46%
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies. What people don’t realize is that those weight-loss drugs come with high valuations and equities that reflect most of the profits they will generate. Consequently, investing in firms with lower valuations that are focused on improving or developing superior weight-loss treatments is a better way to go. Here are three weight-lo

InvestorPlace 2 months ago

BHVN
-0.46%
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted substantial progress and outlined 2024 milestones related to its broad portfolio at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. A copy of the slide presentation is available on the Events and Presentations section of the B

PR Newswire 3 months ago

BHVN
-0.46%
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 8, 2024 at 8:15 am (PT).

PR Newswire 3 months ago

BHVN
-0.46%
Director Irina Antonijevic Sells 11,000 Shares of Biohaven Ltd (BHVN)

Irina Antonijevic, a director at Biohaven Ltd (NYSE:BHVN), has sold 11,000 shares of the company on December 29, 2023, according to a recent SEC Filing.

GuruFocus.com 3 months ago

BHVN
-0.46%
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting

Biohaven Ltd. (NYSE: BHVN) announced today that it is presenting expanded EEG and safety data for BHV-7000 at the 2023 American Epilepsy Society (AES) Annual Meeting, taking place December 1-5, 2023, in Orlando, Florida. The presentations include results from the BHV-7000 Phase 1 EEG biomarker study and additional BHV-7000 safety and tolerability data from Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) studies. Additional posters showcase BHV-7000's preclinical data, finding

PR Newswire 4 months ago

BHVN
-0.46%
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Biohaven...

Simply Wall St. 5 months ago

BHVN
-0.46%
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

Zacks 5 months ago

BHVN
-0.46%
BPMC
-1.66%
Biohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ...

Key Developments Include Progress in Immunology and CNS Programs, Enhanced by Successful Public Offering

GuruFocus.com 5 months ago

BHVN
-0.46%
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.

PR Newswire 5 months ago

BHVN
-0.46%
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks 5 months ago

BHVN
-0.46%

Performance Overview

Return	BHVN	S&P 500
YTD	-9.95%	+5.84%
1-Year	+177.87%	+22.03%
3-Year	--	+36.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biohaven Ltd. (BHVN)

Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN)

Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?

Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

A Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology

Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Director Irina Antonijevic Sells 11,000 Shares of Biohaven Ltd (BHVN)

Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

Biohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ...

Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments

Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why

Performance Overview